Home › Free Stock Grades › RGNX
REGENXBIO Inc. (RGNX) Stock Grade
RGNX · Healthcare
C
Market Cap
$386.2M
P/E Ratio
—
Revenue Growth (YoY)
+104.5%
Net Margin
-113.8%
Return on Equity
—
Dividend Yield
None
About REGENXBIO Inc.'s fundamentals
REGENXBIO is a biotechnology company with a market capitalization of $386.2 million that demonstrated strong revenue growth of 104.5% year-over-year, indicating expanding commercial activity or licensing arrangements. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -113.8%, meaning expenses significantly exceed revenues. The company does not pay a dividend, which is typical for early-stage biotech firms, and the lack of earnings data reflects its pre-profitability stage of development.